During the past 12 months, Egyptian International Pharmaceutical Investments's average Dividends Per Share Growth Rate was 50.00% per year.
During the past 3 years, the average Dividends Per Share Growth Rate was -4.10% per year.
During the past 5 years, the average Dividends Per Share Growth Rate was -11.50% per year.
During the past 10 years, the average Dividends Per Share Growth Rate was -0.30% per year.
During the past 13 years, the highest 3-Year average Dividends Per Share Growth Rate of Egyptian International Pharmaceutical Investments was 44.30% per year. The lowest was -21.10% per year. And the median was 5.80% per year.
The growth rate is calculated with least square regression.
For more information regarding to dividend, please check our Dividend Page.
* Please note that "special dividend" is not included in the calculation of dividend per share and related fields.
Egyptian International Pharmaceutical Investments (CAI:PHAR) Dividend Yield % Explanation
Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.
Dividends may also qualify a lower tax rate for investors.
In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Egyptian International Pharmaceutical Investments Dividend Yield % Chart
Egyptian International Pharmaceutical Investments Annual Data
CAI:PHAR vs ZTS, UTHR, VTRS: Dividend Yield % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Egyptian International Pharmaceutical Investments's Dividend Yield %, along with its competitors' market caps and Dividend Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Egyptian International Pharmaceutical Investments Dividend Yield % vs Drug Manufacturers Industry
Egyptian International Pharmaceutical Investments Dividend Yield % Calculation
Dividend Yield measures how much a company pays out in dividends each year relative to its share price.
Egyptian International Pharmaceutical Investments Recent Full-Year* Dividend History
Amount
Ex-date
Record Date
Pay Date
Type
Frequency
Forex Rate
EGP 3.500000
2026-04-28
2026-04-29
0000-00-00
Cash Dividend
annually
EGP:EGP 1.000000
* GuruFocus has an internal rule that if the most recent dividend payment frequency is at least 4 times a year, then the full year will be calculated according to the frequency of payment or the one-year time frame, whichever is stricter.
* GuruFocus converts dividend currency to local traded share price currency in order to calculate dividend yield. Please refer to the last column "Forex Rate" in the above table.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Egyptian International Pharmaceutical Investments (CAI:PHAR) has a Dividend Yield % of 3.95% as of Jun. 27, 2026. Dividend yield is the ratio of company dividends to the share price. View historical data on Egyptian International Pharmaceutical Investments and its competitors. This is 18% below median its historical median of 4.80. Over the past decade, Egyptian International Pharmaceutical Investments' Dividend Yield % has ranged from 2.33 to 10.68. According to the industry distribution chart, Egyptian International Pharmaceutical Investments ranks #108 out of 516 companies in the Drug Manufacturers industry, placing it in the top 20.9%.
Is Egyptian International Pharmaceutical Investments' Dividend Yield % too high?
Egyptian International Pharmaceutical Investments' current Dividend Yield % of 3.95% is 18% below median its 10-year median of 4.80. Over the past 10 years, this metric has ranged from a low of 2.33 to a high of 10.68. The Drug Manufacturers industry median Dividend Yield % is 2.03. Egyptian International Pharmaceutical Investments' value of 3.95% is 94.6% above this industry median. Based on the distribution chart, Egyptian International Pharmaceutical Investments ranks #108 out of 516 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Egyptian International Pharmaceutical Investments has a GF Score™ of 69/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Egyptian International Pharmaceutical Investments' Dividend Yield % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Egyptian International Pharmaceutical Investments ranks #108 out of 516 companies for Dividend Yield %. This places Egyptian International Pharmaceutical Investments in the top 21% of its industry — outperforming the majority of peers. The industry median Dividend Yield % is 2.03. Egyptian International Pharmaceutical Investments' value of 3.95% is 94.6% above this benchmark. Historically, Egyptian International Pharmaceutical Investments' own Dividend Yield % has ranged from 2.33 to 10.68 over the past decade. While the company's 10-year median is 4.80 vs. the industry median of 2.03, Egyptian International Pharmaceutical Investments has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Dividend Yield % for a Drug Manufacturers company?
The median Dividend Yield % among Drug Manufacturers companies is 2.03, based on 516 companies in the industry. Companies in the top quartile (top 25%) have a Dividend Yield % significantly above this median, while those in the bottom quartile fall well below. However, Dividend Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Egyptian International Pharmaceutical Investments's current Dividend Yield % of 3.95% is 94.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Dividend Yield % mean?
A high Dividend Yield % can signal that a stock is expensive relative to its fundamentals. Dividend yield is the ratio of company dividends to the share price. View historical data on Egyptian International Pharmaceutical Investments and its competitors. For the Drug Manufacturers industry, the median Dividend Yield % is 2.03 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Egyptian International Pharmaceutical Investments's current Dividend Yield % is 3.95%, which is 18% below median its own 10-year median of 4.80. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Egyptian International Pharmaceutical Investments stock overvalued right now?
Based on GuruFocus' analysis, Egyptian International Pharmaceutical Investments (CAI:PHAR) is currently considered Significantly Overvalued. The stock's GF Value™ is E£59.67, compared to a current price of E£88.50 — trading 48.3% above its estimated fair value. The current Dividend Yield % is 3.95%, which is 18% below median its 10-year median of 4.80 and 94.6% above the Drug Manufacturers industry median of 2.03. Egyptian International Pharmaceutical Investments' overall GF Score™ is 69/100 with 12 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Dividend Yield % calculated?
Dividend Yield % is calculated from a company's financial statements. For Egyptian International Pharmaceutical Investments (CAI:PHAR), the current Dividend Yield % is 3.95% as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Egyptian International Pharmaceutical Investments (CAI:PHAR) Overvalued in 2026?
Based on GuruFocus' analysis, Egyptian International Pharmaceutical Investments stock appears to be overvalued.
The current stock price of E£88.50 is trading 48.3% above its estimated GF Value™ of E£59.67.
GuruFocus considers Egyptian International Pharmaceutical Investments to be Significantly Overvalued.
Key valuation signals for CAI:PHAR:
Dividend Yield %: 3.95% (18% below median its 10-year median of 4.80)
GF Value™: E£59.67 vs. price of E£88.50 (48.3% above fair value)
Industry Position: 94.6% above the Drug Manufacturers median (#108 of 516)
No single metric tells the full story. See the CAI:PHAR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Egyptian International Pharmaceutical Investments Business Description
Egyptian International Pharmaceutical Investments is an Egypt based company pharmaceutical generic drugs. It holds license agreements with a group of pharmaceutical companies to produce their products locally and replace the imported ones. The company produces dosage forms, Spansule capsules, Antibiotics, Lyophilized Products. It exports its products to African, Asian and East European and Latin American Countries.
69GF Score
Get the complete analysis for CAI:PHAR
Dividend Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CAI:PHAR has been successfully added to your 
